The recent run of good fortune for vaccine maker Novavax (NASDAQ:NVAX continues. Following the major licensing deal with ...
Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled ...
Shah Capital, a top shareholder of Novavax (NASDAQ:NVAX), has withdrawn its proxy campaign against the company days after the ...
Sanofi on Friday said it had reached a deal worth up to $1.2 billion to sell Novavax’s Covid shot as well as to try to ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi ...
Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's board, after the COVID-19 vaccine maker struck a licensing deal with ...
Sanofi and Novavax signed a licensing agreement that includes commercialising a combined Covid-19 and flu shot. Read more at ...
Novavax shares jumped 50% on Monday following its recent licensing deal with Sanofi, as meme stocks are making a 2021-style ...
Novavax (NVAX) shares are skyrocketing after the company announced a $1.2 billion deal with French drugmaker Sanofi (SNY). B.
Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company’s fiscal Q1 2024 ...
STORY: Shares of vaccine maker Novavax spiked as much as 146% on Friday, after announcing it had struck a licensing deal with ...